AstraZeneca PLC (AZN)vsSurrozen Inc (SRZN)
AZN
AstraZeneca PLC
$185.95
-0.83%
HEALTHCARE · Cap: $282.69B
SRZN
Surrozen Inc
$21.52
-11.73%
HEALTHCARE · Cap: $280.97M
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 806399% more annual revenue ($60.44B vs $7.49M). AZN leads profitability with a 17.2% profit margin vs 0.0%. AZN earns a higher WallStSmart Score of 64/100 (C+).
AZN
Buy64
out of 100
Grade: C+
SRZN
Avoid34
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+8.2%
Fair Value
$194.77
Current Price
$185.95
$8.82 discount
Intrinsic value data unavailable for SRZN.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 22 in profit
Strong operational efficiency at 27.9%
Generating 1.8B in free cash flow
Revenue surging 408.6% year-over-year
Conservative balance sheet, low leverage
Areas to Watch
Moderate valuation
Distress zone — elevated risk
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.2% and operating margin at 27.9%. Revenue growth of 12.5% demonstrates continued momentum.
Bull Case : SRZN
The strongest argument for SRZN centers on Revenue Growth, Debt/Equity. Revenue growth of 408.6% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Altman Z-Score.
Bear Case : SRZN
The primary concerns for SRZN are EPS Growth, Market Cap, Profit Margin.
Key Dynamics to Monitor
AZN profiles as a mature stock while SRZN is a hypergrowth play — different risk/reward profiles.
SRZN carries more volatility with a beta of 0.59 — expect wider price swings.
SRZN is growing revenue faster at 408.6% — sustainability is the question.
AZN generates stronger free cash flow (1.8B), providing more financial flexibility.
Bottom Line
AZN scores higher overall (64/100 vs 34/100), backed by strong 17.2% margins and 12.5% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Surrozen Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Surrozen Inc. is a clinical-stage biopharmaceutical company dedicated to advancing innovative therapeutics through its proprietary SIRPa-IgG platform, which focuses on modulating targeted immune responses. The company's diverse pipeline features novel antibody therapeutics aimed primarily at addressing serious oncological and autoimmune conditions, underlining its commitment to tackling significant unmet medical needs. With a solid foundation in research and development and strategic collaborations, Surrozen is well-positioned to deliver transformative therapies, highlighting its potential for substantial growth and impact in the biopharmaceutical sector.
Visit Website →Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?